Laminins, a family of extracellular matrix glycoproteins, are the major non-collagenous constituent of basement membranes. They have been implicated in a wide variety of biological processes including cell adhesion, differentiation, migration, signaling, neurite outgrowth and metastasis. Many of the effects of laminin are mediated through interactions with cell surface receptors. These receptors include members of the integrin family, as well as non-integrin laminin-binding proteins. This gene encodes a high-affinity, non-integrin family, laminin receptor 1. Reportedly, level of laminin receptor transcript is higher in colon carcinoma tissue and lung cancer cell line than their normal counterparts. Also, there is a correlation between the upregulation of this polypeptide in cancer cells and their invasive and metastatic phenotype. (Shipping Cost: €200.00)

CD15/FUT4 [Carb-3]

CD15 is a complex cluster of cell surface glycoproteins and glycolipids with a common trisaccharide structure, 3-fucosyl-N-acetyllactosamine (3-FL), also referred to as Lewis X (LeX) antigen. This antigen is involved in neutrophil functions such as, cell-cell interactions, phagocytosis, stimulation of degranulation and respiratory burst. The CD15 is expressed in Reed-Sternberg cells, myeloid cells as well as epithelial cells. CD15 antibody has been used as an immunohistochemical marker to identify Reed-Sternberg cells (RSC) in Classical Hodgkin Lymphoma (CHL).. CD15 is expressed on Reed-Sternberg cells of Hodgkin’s disease and by various other cell types including myeloid cells and epithelial cells. Antibodies to CD15 recognize a pentasaccharide sequence occurring in lacto-N-fucopentaose III ceramide (also referred to as X hapten of Lex) found in higher glycolipids and glycoproteins. A review by Arber et al. has reported that antibodies to CD15 demonstrate positive staining in 87% of Hodgkin’s disease including nodular sclerosing, mixed cellularity, and lymphocyte depletion, wherea s the lymphocyte predominant variant exhibits a lower rate of positivity (37%). Among non-Hodgkin’s lymphoma, 13% express CD15 including 4.1% B-cell, 21% T-cell, and 17% null-cell. CD15 expression has also been demonstrated in acute myeloid leukemia (65%) and chronic myelogenous leukemia (96% chronic phase and 54% blast phase). A relatively low level of CD15 expression has been reported in acute lymphoblastic leukemia (5.7% overall) with positivity observed in 7.7% common or precursor B-cell, 0% B-cell, 7.7% T-cell and 17.3% null-cell. Carcinomas derived from various organs have also been shown to be CD15 positive (56%) including adenocarcinomas, squamous cell carcinomas and undifferentiated large and small cell carcinomas.

CD15/FUT4 [Carb-3]